Launch Date
07/24/2023 at 4:00 am EST
Credit Amount
0.5
Credit Expires
12/31/2025
IH is characterized by excessive daytime sleepiness (EDS), severe sleep inertia, and prolonged, non-restorative nighttime sleep. Patients with IH report experiencing brain fog, poor memory, and sleep drunkenness, even though 50% of patients report sleeping 10 hours or more nightly. Quality of life (QoL) is worse in patients with IH compared to healthy patients, with IH contributing to worsened cognition, poor daily functioning, work absenteeism, and depression. However, clinician understanding of IH is poor, and recognition of signs and symptoms of IH may not be adequate. Findings indicate that patients can wait up to 5-10 years for a diagnosis to be given, indicating that clinicians lack familiarity with IH and the ability to correlate symptoms with the disease.
In this CMEO BriefCase, entitled Recognizing IH: The Patient Diagnostic Journey, expert faculty will walk through a case-driven discussion on the significant impact of symptoms on QoL and work/psychosocial functioning for patients with IH, and how this leads to delays in screening and diagnosis.
Screen for IH based on clinical presentation or patient or family/caregiver description of function and changes in QoL.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Sleep specialists, primary care physicians, pulmonologists, neurologists, psychiatrists, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Thorpy reports the following financial relationships:
Advisory Board/Consultant: Alkermes; Axsome Therapeutics, Inc.; Balance Therapeutics; Eisai Inc.; Flamel Technologies/Avadel; Harmony Biosciences; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; NLS Pharmaceutics; Suven Life Sciences Ltd.; Takeda Pharmaceuticals U.S.A., Inc..; and XWPharma Ltd.
Dr. Doghramji reports the following financial relationships:
Advisory Board: Bayer; Eisai Inc.; and Idorsia Pharmaceuticals Ltd.
Speakers Bureau: AbbVie Inc. Eisai Inc.; Idorsia Pharmaceuticals Ltd; and Merck & Co., Inc.
Stock Shareholder (directly purchased): CVS Health Corporation and Pfizer Inc.
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
Call us at 877.CME.PROS (877.263.7767).
BC-090-072423-43